Check your email seventeen times before lunch, and nobody hands you a diagnosis. Reorganize the same closet three times in a week, and it barely registers as strange. But the anxiety spike when a phone battery dips below twenty percent, the urge to recheck a locked door, the inability to stop even when you genuinely […]
The post Compulsive Behaviors Can Develop Without Substance Use appeared first on Medical News Bulletin.
The FDA has granted accelerated approval to sevabertinib as first-line treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer.
The approval of sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals), which expands upon the agent’s existing indication for patients who received systemic therapy, is dependent on the detection of HER2 tyrosine kinase domain activating tumors.
The FDA said in a press release that it based its decision on the single-arm, phase 1/2 SOHO-01 trial, which showed an objective response rate of 75% (95% CI, 64%-85%).
The trial
Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA accepted a biologics license application for Mogenry, Nanoscope Therapeutics’ investigational therapy designed for vision restoration in retinitis pigmentosa, according to a press release.
Mogenry (sonpiretigene isteparvovec), also known as MCO-010, is a one-time intravitreal optogenetic gene therapy. If the therapy is approved, the company said it would be the first gene-agnostic therapy to improve vision in patients with severe vision loss from retinitis pigmentosa.
The submission was supported by the
Flow Neuroscience announced the launch of FL-100, the first at-home transcranial direct current stimulation treatment for moderate to severe depression, in the United States.
FL-100, approved by the FDA in December 2025, “gives patients and clinicians another evidence-based option and a fundamentally different way of approaching depression treatment,” Daniel Månsson, CEO and co-founder of Flow Neuroscience, said in a press release.
The manufacturer said the headset is approved as monotherapy or adjunctive therapy in patients aged 18 years or older “who are not considered treatment-refractory to
Among patients in rehab for traumatic brain injury, the initial severity of injury was not significantly correlated with functional status, but metrics from a bedside eye-tracking system were, according to a study in Frontiers in Neurology.
“Eye movements are commonly examined after neurological injury, but in routine clinical practice, smooth pursuit is often assessed qualitatively by asking a patient to follow a handheld target,” study authors Shimrit Shani, a PhD student in the School of Optometry and Vision Science at Bar-Ilan University, Israel, and Yoram S. Bonneh, PhD, professor at the
PARK CITY, Utah — While menopause usually occurs in women around the age of 52 years, perimenopause can begin 10 years before menopause and can be associated with joint pain and bone loss, according to a presenter here.
“Interestingly, some of the major long-term consequences of the menopausal transition are not what you think they are. Many of them are orthopedic,” Jocelyn Wittstein, MD, associate professor of orthopedic surgery at Duke University Medical Center, said in her presentation at the International Extreme Sports Medicine Congress.
In fact, Wittstein said bone
People with invasive cancer may be more likely to experience ischemic stroke, according to results of a retrospective cohort study.
Risk — which varied considerably by cancer type — appeared particularly elevated in the first few months after diagnosis.
This establishes “a critical window” for targeted assessment and intervention, according to lead author Carmit Libruder, MSc, researcher with University of Haifa and the Israel Ministry of Health.
“Our findings reinforce the importance of a multidisciplinary approach to cancer care,” Libruder told Healio. “Cancer treatment is, of course, central
Adalimumab, a tumor necrosis factor inhibitor, was associated with an early reduction in epicardial adipose tissue in people with psoriasis, according to a post hoc analysis published in Psoriasis: Targets and Therapy.
The reduction was independent of weight loss or psoriasis activity, the researchers reported.
“These findings suggest a treatment-specific effect of [tumor necrosis factor (TNF)] inhibition on a high-risk cardiac fat depot in psoriasis,” Ravi Ramessur, MD, PhD, an academic dermatology consultant at King’s College London and post-doctoral clinical-academic research fellow at the
A 22-year-old woman of East Asian descent was referred to Tufts Medical Center for bilateral blurry vision over the past 7 years.
She had seen four different optometrists over the past year who were unable to correct her visual acuity to better than 20/40. Given a lack of explanation for why her vision was unable to be corrected beyond 20/40, she was referred for further evaluation.
Since the onset of symptoms, her blurry vision has remained subjectively stable. She denied photopsia, nyctalopia and scotomas. She had no history of strabismus, amblyopia or patching.
Her medical history was notable
MUNICH — A novel oral relaxin receptor agonist was well tolerated and had favorable effects on hemodynamics in patients with heart failure across the ejection fraction spectrum, researchers reported.
For the phase 2b LUMINARA trial, presented at the European Society of Cardiology Congress and simultaneously published in Circulation, researchers evaluated AZD5462 (AstraZeneca) in two cohorts: Cohort A included 235 patients with HF and left ventricular ejection fraction 35% or less (mean age, 65 years; 88% men) and cohort B included 140 patients with HF and LVEF 41% to 55% (mean age, 70 years;